Anticancer drug targets: Cell cycle and checkpoint control

Journal of Clinical Investigation

Volumn 104, Issue 12, 1999, Pages 1645-1653

  Shapiro, Geoffrey I ^a,c   Harper, J Wade ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL;

CANCER; CELL ACTIVITY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL TRANSFORMATION; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG TARGETING; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 0033399453     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9054     Document Type: Review

References (44)

1. Hartwell, L.H., and Kastan, M.B. 1994. Cell cycle control and cancer. Science. 266:1821-1828.
2. Harbour, J.W., Luo, R.X., DeiSanti, A., Postigo, A.A., and Dean, D.C. 1999. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 98:859-869.
3. Sherr, C.J., and Roberts, J.M. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
4. van den Heuvel, S., and Harlow, E. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 262:2050-2054.
5. INK4a-mediated growth suppression. Mol. Cell Biol. 18:5284-5290.
6. Eastham, J.A., et al. 1995. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 55:5151-5155.
7. INK4 gene mediated by an adenovirus vector. Cancer Res. 55:3250-3253.
8. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med. 3:313-319.
9. Kipl in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene. 18:1663-1676.
10. INK4a in mesothelioma cells results in cell cycle arrest, cell death, rumor suppression and tumor regression. Oncogene. 16:3087-3095.
11. INK4 expression is associated with increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn. J. Cancer Res. 88:1009-1016.
12. Katayose, Y., et al. 1997. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 57:5441-5445.
13. Meijer, L. 1996. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6:393-397.
14. Meijer, L., and Kim, S.H. 1997. Chemical inhibitors of CDKs. Methods Enzymol. 283:113-128.
15. Sedlacek, H.H., et al. 1996. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9:1143-1168.
16. De Azevedo, W.F., et al. 1996. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA. 93:2735-2740.
17. Kaur, G., et al. 1992. Growth inhibition with reversible cell cycle arrest of carcinoma cells by Flavone L86-8275. J. Natl. Cancer Inst. 84:1736-1740.
18. Carlson, B.A., Dubay, M.M., Sausville, E.A., Brizuela, L., and Worland, P.J. 1996. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human bteast carcinoma cells. Cancer Res. 56:2973-2978.
19. Carlson, B., et al. 1999. Down-regulation of cyclin D1 by transcripdonal repression in MCF-7 human breast carcinoma cells induced by Flavopiridol. Cancer Res. 59:4634-4641.
20. Akiyama, T., et al. 1997. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of Cdk inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 57:1495-1501.
21. Chen, X., Lowe, M., and Keyomarsi, K. 1999. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene. 18:5691-5702.
22. Seynaeve, C.M., et al. 1993. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res. 53:2081-2086.
23. Mack, P.C., et al. 1999. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin. Cancer Res. 5:2596-2604.
24. Bible, K.C., and Kaufmann, S.H. 1996. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. CancerRes. 56:4856-4861.
25. Shao, R.G., Shimizu, T., and Pommier, Y. 1997. 7-hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Exp. Cell Res. 234:388-397.
26. Senderowicz, A.M., et al. 1998. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16:2986-2999.
27. Sausville, E.A., et al. 1998. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother. Pharmacol. 42:S54-59.
28. Gray, N.S., et al. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:533-538.
29. Lundgren, K., et al. 1999. Novel cyclin-dependent kinase inhibitors with potent growth-inhibitory action. Proc. Am. Assoc. Cancer Res. 40:A2022. (Abstr.)
30. Walker, D.H., et al. 1999. The novel cyclin dependent kinase inhibitors, GW5181 and GW9499 regulate cell cycle progession and induce tumor-selective cell death. Proc. Am. Assoc. Cancer Res. 40:A4783. (Abstr.)
31. Sugiyama, K., et al. 1999. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-hydroxystaurosporine). Cancer Res. 59:4406-4412.
32. Krek, W., Xu, G., and Livingston, D.M. 1995. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 83:1149-1158.
33. Chen, Y.N.P., et al. 1999. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Prof. Natl. Acad. Sci. USA. 96:4325-4329.
34. Bible, K.C., and Kaufmann, S.H. 1997. Cytotoxic synergy between Flavopiridol and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 57:3375-3380.
35. Schwartz, G.K., Farsi, K., Maslak, P., Kelsen, D.P., and Spriggs, D. 1997. Potentiation of apoptosis by Flavopiridol in Mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res. 3:1467-1472.
36. Weinert, T. 1997. A DNA damage checkpoint meets the cell cycle engine. Science. 277:1450-1451.
37. Bunz, F., et al. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1497-1501.
38. Chan, T.A., Hermeking, H., Lengauer, C., Kinzler, K.W., and Vogelstein, B. 1999. 14-3-3-σ is required to prevent mitotic catastrophe after DNA damage. Nature. 401:616-620.
39. Waldman, T., Lengauer, C., Kinzler, K.W., and Vogelstein, B. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:713-716.
40. Sarkaria, J.N., et al. 1999. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59:4375-4382.
41. Powell, S.N., et al. 1995. Differential sensitivity of p53- and p53+ cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 55:1643-1648.
42. Wang, Q., et al. 1996. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88:956-965.
43. Yu, L., et al. 1999. The checkpoint kinase Chk1 is a target of the anticancer agent UCN-01. Proc. Am. Assoc. Cancer Res. 40:A2019. (Abstr.)
44. Stepanova, L., Leng, X., Parker, S.B., and Harper, J.W. 1996. Mammalian p50cdc37 is a protein-kinase targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 10:1491-1502.